Current Articles in the field of Food Chemistry published online in scientific journals.
The author- or copyrights of the listed
research articles below
are held by the respective authors or site operators, who are also responsible
for the content of the presentations.
To search
this web page for specific words type "Ctrl" + "F" on your keyboard
(Command + "F" on a Mac). Then: type the word you are searching for in
the window that pops up!
To list your
article here plaease contact us by eMail.
On this page considered biochemistry journals:
Journal of Agricultural and Food Chemistry - published by
The American Chemical Society -
Chemistry and biochemistry of agriculture and food along with safety, composition and processing; including feeds, pesticides, veterinary drugs, plant growth regulators, fertilizers, and other agro-chemicals with their metabolism, toxicology, and environmental fate and the chemical processes involved in nutrition, phytonutrients, flavors, and aromas.
Molecular Nutrition & Food Research - published by
Wiley-Interscience -
... is a primary research journal devoted to health, safety and all aspects of molecular nutrition such as nutritional biochemistry, nutrigenomics and metabolomics
European Food Research and Technology - published by
Springer -
The journal's mission is the fast publication of high quality papers on front-line research, new and novel techniques and developing trends in such disciplines as chemistry and biochemistry; technology and molecular biotechnology; nutritional chemistry and toxicology; analytical and sensory methodologies and food physics.
Chemical Senses - published by
Oxford Journals -
... publishes original research and review papers on all aspects of chemoreception in both humans and animals.
Annals of Nutrition and Metabolism - published by
Karger -
The editors of this journal show their dedication to this search by carefully selecting basic and clinical reports offering new information relating to human nutrition and metabolic diseases including their molecular genetics
Current research articles of the mentioned
journals:
Cecilia Shiroma-Kian, David Tay, Iván Manrique, M. Monica Giusti, and Luis E. Rodriguez-Saona Web Release Date: Fri, 3 Oct 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801716b
Rafael Rodríguez-Acuña, María del Carmen Pérez-Camino, Arturo Cert, and Wenceslao Moreda Web Release Date: Fri, 3 Oct 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8016699
Carla M. Oliveira, António C. S. Ferreira, Paula G. Pinho, and Artur M. S. Silva Web Release Date: Thu, 2 Oct 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8013662
Shiying Tian, Xiuhua Fang, Weimin Wang, Bingwu Yu, Xiaofang Cheng, Feng Qiu, Andrew J. Mort, and Ruth E. Stark Web Release Date: Thu, 2 Oct 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801028g
Nam Joo Kang, Kyung Mi Lee, Jong Hun Kim, Bo Kyung Lee, Jung Yeon Kwon, Ki Won Lee, and Hyong Joo Lee Web Release Date: Thu, 2 Oct 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801981w
Maria Rosecler Miranda Rossetto, João Roberto Oliveira do Nascimento, Eduardo Purgatto, João Paulo Fabi, Franco Maria Lajolo, and Beatriz Rosana Cordenunsi Web Release Date: Wed, 1 Oct 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801934x
Miguel A. Cantarelli, Roberto G. Pellerano, Eduardo J. Marchevsky, and José M. Camiña Web Release Date: Wed, 1 Oct 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801972q
José C. del Río, Jorge Rencoret, Gisela Marques, Ana Gutiérrez, David Ibarra, J. Ignacio Santos, Jesús Jiménez-Barbero, Liming Zhang, and Ángel T. Martínez Web Release Date: Tue, 30 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf800806h
Annetta Hartmann, Claus-Dieter Patz, Wilfried Andlauer, Helmut Dietrich, and Michael Ludwig Web Release Date: Sat, 27 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801555q
Jocelyn I. Dudley, Istvan Lekli, Subhendu Mukherjee, Manika Das, Alberto A. A. Bertelli, and Dipak K. Das Web Release Date: Sat, 27 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801791d
Bei Jiang, James T. Lyles, Kurt A. Reynertson, Fredi Kronenberg, and Edward J. Kennelly Web Release Date: Fri, 26 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf802481w
Lúcia Oliveira, Carmen S. R. Freire, Armando J. D. Silvestre, and Nereida Cordeiro Web Release Date: Fri, 26 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801709t
Mia Isabelle, Bee Lan Lee, Choon Nam Ong, Xueming Liu, and Dejian Huang Web Release Date: Fri, 26 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801527a
Ricard Bou, Francesc Guardiola, Rafael Codony, Cameron Faustman, Ryan J. Elias, and Eric A. Decker Web Release Date: Thu, 25 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8009848
Edgar Escalante-Sánchez, Daniel Rosas-Ramírez, Edelmira Linares, Robert Bye, and Rogelio Pereda-Miranda Web Release Date: Thu, 25 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801973m
Joseph Y. N. Philip, José Da Cruz Francisco, Estera S. Dey, Joseph Buchweishaija, Lupituko L. Mkayula, and Lei Ye Web Release Date: Wed, 24 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801532a
Luiz C. A. Barbosa, Ulisses A. Pereira, Róbson R. Teixeira, Célia R. A. Maltha, Sergio A. Fernandes, and Giuseppe Forlani Web Release Date: Tue, 23 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf802077e
Nicolai D. Jablonowski, Stephan Koeppchen, Diana Hofmann, Andreas Schaeffer, and Peter Burauel Web Release Date: Tue, 23 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8017832
Francesca Masino, Giuseppe Montevecchi, Giuseppe Arfelli, and Andrea Antonelli Web Release Date: Tue, 23 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8015893
Seong-Cheol Park, Nae Choon Yoo, Jin-Young Kim, Hae Kyun Park, Byung Jo Chae, Song Yub Shin, Hyeonsook Cheong, Yoonkyung Park, and Kyung-Soo Hahm Web Release Date: Sat, 20 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf802373h
Trine Torgersen, Christopher O. Miles, Thomas Rundberget, and Alistair L. Wilkins Web Release Date: Fri, 19 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8016749
Pu Jing, Joshua A. Bomser, Steven J. Schwartz, Jian He, Bernadene A. Magnuson, and M. Mónica Giusti Web Release Date: Fri, 19 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8005917
Antonio López-López, Rafael López, Fernando Madrid, and Antonio Garrido-Fernández Web Release Date: Fri, 19 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801690k
A. J. Signes-Pastor, K. Mitra, S. Sarkhel, M. Hobbes, F. Burló, W. T. de Groot, and A. A. Carbonell-Barrachina Web Release Date: Fri, 19 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801600j
William Yajima, Muhammad H. Rahman, Dipankar Das, Mavanur R. Suresh, and Nat N. V. Kav Web Release Date: Fri, 19 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf801768g
Sylvio Botelho-Júnior, César L. Siqueira-Júnior, Bruno C. Jardim, Olga L. T. Machado, Ana G. C. Neves-Ferreira, Jonas Perales, and Tânia Jacinto Web Release Date: Wed, 17 Sep 2008 00:00:00 EDT (Article) DOI: 10.1021/jf8013266
To examine the carry over of deoxynivalenol (DON) and its metabolite de-epoxy DON (DOM-1) in milk, lactating German Holstein cows (n = 13) were fed an isoenergetic total mixed ration in Period 1 with 50% concentrates and 5.3 mg DON/kg dry matter (DM) over 11 wk and were compared with control cows (n = 14). In Period 2 (18 wk), an elevated concentrate proportion was compared to a low concentrate ration by dividing the cows into four Groups (n = 8): Control-30 (30% concentrates), Myco-30 (30% concentrates, 4.4 mg DON/kg DM), Control-60 (60% concentrates) and Myco-60 (60% concentrates, 4.6 mg DON/kg DM). Taken both periods together, no unmetabolised DON was detected in milk samples using the HPLC-UV method. DOM-1 concentrations ranged between below the LOD and 3.2 [mu]g/kg milk in mycotoxin fed cows, while control cows did not excrete any measurable amounts of DOM-1. Regarding the concentrate effects, the carry over of DON as DOM-1 in milk was negligible (between 0.0001 and 0.0011) but significantly higher in Group Myco-30 than in Group Myco-60. This effect may result from an altered bioavailability of DON from maize silage which made up a higher proportion of the daily ration.
Mitogen-activated protein kinase (MAPK) pathways play central roles in the transduction of extracellular stimuli into cells and the regulation of expression of numerous genes. Docosahexaenoic acid (DHA) was shown to be involved in the regulation of expression of drug metabolizing enzymes (DMEs) in rat primary hepatocytes in response to xenobiotics. Cytochrome P450 2B1 (CYP 2B1) is a DME that is dramatically induced by phenobarbital-type inducers. The constitutive androstane receptor (CAR) plays a critical role in regulating the expression of DMEs, and the phosphorylation/dephosphorylation of CAR is an important event in CYP 2B1 expression. In the present study, we determined the effect of DHA on MAPK transactivation and its role in CYP 2B1 expression induced by phenobarbital. c-Jun NH2-terminal kinase (JNK) JNK1/2 and ERK1/2 were activated by phenobarbital in a dose-dependent manner. DHA (100 [mu]M) inhibited JNK1/2 and ERK2 activation induced by phenobarbital in a time-dependent manner. Both SP600125 (a JNK inhibitor) and SB203580 (a p38 MAPK inhibitor) inhibited CYP 2B1 protein and mRNA expression induced by phenobarbital. SB203580 significantly increased the intracellular 3[prime]-5[prime]-cyclic adenosine monophosphate (cAMP) concentration compared with a control group (p < 0.05). Our results suggest that inhibition of JNK activation by DHA is at least part of the mechanisms of DHA's downregulation of CYP 2B1 expression induced by phenobarbital.
Information about lipid oxidation in fresh and stored human milk compared with infant formulas is scarce. We aimed to assess n-6 and n-3 PUFA oxidation in these milks by measuring the 4-hydroxynonenal (4-HNE) and 4-hydroxyhexenal (4-HHE) content. Human milk samples (n = 4), obtained from volunteer mothers, were analyzed fresh and after 1 wk at 4°C or 24 h at 18°C. Vitamin E and malondialdehyde (MDA) were measured by HPLC and fatty acid profile by GC. The 4-HHE and 4-HNE contents were measured by GC-MS. Infant formulas (n = 10) were tested; their fat droplet size was measured by laser light scattering and observed by confocal laser scanning microscopy. Human milk samples contained 31.0 ± 6.3 g/L of lipids and 1.14 ± 0.26 mg/L of vitamin E. Fat droplets were smaller in infant formulas than reported in human milk. The (4-HHE/n-3 PUFA) ratio was 0.19 ± 0.01 [mu]g/g in fresh human milk (unchanged after storage) versus 3.6 ± 3.1 [mu]g/g in dissolved powder formulas and 4.3 ± 3.8 [mu]g/g in liquid formula. (4-HNE/n-6 PUFA) was 0.004 ± 0.000 [mu]g/g in fresh milk (0.03 ± 0.01 [mu]g/g after storage) versus 1.1 ± 1.0 [mu]g/g in dissolved powder formulas and 0.2 ± 0.3 [mu]g/g in liquid formula. Infant formulas also contained more MDA than human milk. n-3 PUFA were more prone to oxidation than n-6 PUFA. Whether threshold levels of 4-HHE and 4-HNE would be of health concern should be elucidated.
Prostate and colorectal cancers are among the most common cancers and identifying modifiable risk factors are important steps to reduce the burden of these severe diseases. Results from several but mostly small observational studies as well as the secondary analysis of an intervention trial provide support for a chemopreventive effect of selenium on prostate and colorectal cancers. Results suggest effect modification by gender and smoking, but this interpretation is limited by the statistical power of previous studies. Several cancer preventive mechanisms have been described and it is likely that selenium acts through multiple pathways. In particular, the anti-oxidative and anti-inflammatory effects mediated through activity of selenoenzymes are discussed, given the relevance of oxidative stress and inflammation in these cancers. Genetic variation in selenoenzymes may modify the potential chemopreventive effect of selenium and need to be further investigated. Additional large observational studies using biomarkers of selenium intake and intervention trials, such as the Selenium and Vitamin E Cancer Prevention Trial, will be important to further evaluate the potential chemopreventive effect of selenium. Furthermore, characterization of functional effects of polymorphisms in selenoenzymes is needed.
Egg proteins represent one of the most important sources evoking food allergic reactions. In order to improve allergy diagnosis, purified and well-characterized proteins are needed. Although the egg white allergens Gal d 1, 2, 3 and 4 (ovomucoid, ovalbumin, ovotransferrin, and lysozyme) are commercially available, these preparations contain impurities, which affect exact in vitro diagnosis. The aim of the present study was to set up further purification protocols and to extend the characterization of the physicochemical and immunological properties of the final batches. The egg white allergens Gal d 1-4 were purified from commercial preparations, whereas Gal d 5 ([alpha]-livetin) was purified from egg yolk. The final batches of Gal d 1-5 consisted of a range of isoforms with defined tertiary structure. In addition, the IgE binding capacity of the purified egg allergens was tested using allergic patients' sera. The allergen batches will be further used to set up allergen specific diagnostic assays and to screen a larger collection of patients' sera.
Sonicated arsonoliposomes were prepared using arsonolipid with palmitic acid acyl chain (C16), mixed with phosphatidylcholine (PC)-based or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)-based, and cholesterol (Chol) with C16/DSPC/Chol 8:12:10 molar ratio. PEG-lipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine conjugated to polyethylenoglycol 2000) containing vesicles (PEGylated-arsonoliposomes; PC-based and DSPC-based) were also prepared. The cytotoxicity of these arsonoliposomes towards different cancer cells (human promyelocytic leukaemia NB4, Prostatic cancer PC3, human breast adenocarcinoma MDA-MB-468, human T-lymphocyte (MT-4) and also towards human umbilical vein endothelial cells (HUVECs) was evaluated by calculating the arsonoliposome-induced growth inhibition of the cells by the MTT assay. IC-50 values were interpolated from cell number/arsonoliposome concentration curves. The results reveal that all types of arsonoliposomes evaluated significantly inhibit the growth of most of the cancer cells studied (PC3, NB4, MT4) with the exception of the MDA-MB-468 breast cancer cells which were minimally affected by arsonoliposomes; in some cases even less than HUVEC. Nevertheless, for the same cell type the differences between the different types of arsonoliposomes were significant but not proportional to their stability, indicating that the formation of arsonoliposomes with very stable membranes is not a problem for their anticancer activity. Thereby it is concluded that arsonoliposome composition should be adjusted in accordance to their in vivo kinetics and the desired, for each specific application, biodistribution of As and/or encapsulated drug.
Although several studies have aimed to identify mare's milk proteins, only the major whey proteins and some caseins have yet been characterized. Incomplete sequencing of the equine genome and the difficulty of recovering highly hydrophobic proteins mean that little is known to date about the proteins associated with milk fat globules, which have been shown to play an important role in newborns' defense mechanisms. The fat fraction, in particular the distribution of unsaturated fatty acids, has been more extensively studied, but complex lipids are only partially elucidated. This study reports a 2-DE approach combined with a powerful method for de novo protein sequencing, and quali-quantitative data on complex lipid composition determined by high performance TLC (HPTLC) and GC. The presence in mare's milk of long-chain highly unsaturated fatty acids, and the evidence of close similarity between equine and human milk fat globule membrane proteins, support the use of mare's milk for human nutrition.
Prostate cancer (PC) chemoprevention has generated considerable interest in the last decade and selenium and combinations of selenium have been recognized as one of the most efficacious chemopreventive agents against PC. This review focuses on a discussion of the knowledge hitherto gained about the mechanisms of action of the various in vitro and in vivo used selenium compounds and their effects on cellular processes and signaling pathways. We also describe the clinical and preclinical studies that have contributed enormously to the knowledge about dose, duration of exposure, and the chemical form of selenium effective in different scenarios. Even though the jury is still out about whether selenium can be used as a chemopreventive agent in the clinic and whether studies with cell lines and populations at low, medium, or high risk can adequately represent the physiological behavior of this micronutrient, it can safely be said to offer the most diverse spectrum of protective effects against this particular type of cancer which may augur well for its future as a chemopreventive agent.
Well-characterised and immunologically active recombinant allergens are of eminent importance for improvement of diagnostic tools and immunotherapy of allergic diseases. The use of recombinant allergens has several advantages such as the more precise quantification of the active substance compared to allergen extracts and the reduced risk of contamination with other allergenic proteins compared to purified natural allergens. Optimised standard protocols for expression and purification and a detailed physico-chemical characterisation of such recombinant allergens are necessary to ensure consistent quality and comparability of results obtained with recombinant material. In this study the major allergen Pen a 1 of brown shrimp (Penaeus aztecus) was expressed in E. coli and purified in two steps by immobilised metal chelate-affinity chromatography (IMAC) and size-exclusion chromatography. Identity and purity were verified with N-terminal sequencing and peptide mass fingerprinting. Circular dichroism and NMR-spectroscopy indicated an alpha-helical flexible structure of rPen a 1 which is in accordance with the known structure of tropomyosins. Finally, the recombinant allergen proved to be immunologically reactive in IgE Western blot analysis and ELISA. This study provides a protocol for the preparation of recombinant shrimp tropomyosin in standardised quality.
The objective of this study was to determine the impact of knockout of Cu,Zn-superoxide dismutase (SOD1) and Se-glutathione peroxidase-1 (GPX1) on murine bone biomechanical properties. Femora samples were collected from wild-type (WT), SOD1-knockout [SOD1(-/-)] and GPX1-knockout [GPX1(-/-)] female mice (9-wk old, n = 7-8 per genotype) to assay for bone enzyme activities and mechanical properties in three point bending. Prior to testing, all mice were fed a torula yeast diet supplemented with 0.4 mg Se/kg as sodium selenite. Compared with the WT mice, SOD1(-/-) mice displayed a series of reductions (p < 0.05): 24% in body mass, 8% in femoral length, 43% in femoral structural strength, and 32% in bending stiffness. When differences in body size were accounted for, femoral failure moment in SOD1(-/-) mice remained lower (p < 0.05) than that of WT. Femoral tartrate resistant acid phosphatase activity in SOD1(-/-) was 47% greater (p < 0.05) than the WT. In contrast, GPX1(-/-) mice showed no significant differences in femoral mechanical properties from those of WT mice. In conclusion, knockout of SOD1 exerted a greater impact on femoral mechanical characteristics than that of GPX1 in growing mice.
This paper examines the in vitro transepithelial transport of antihypertensive peptides derived from egg proteins using Caco-2 cell monolayers. Ovokinin (FRADHPFL) was absorbed intact through the Caco-2 cell epithelium, although it was also susceptible to the action of brush-border aminopeptidases that yielded shorter fragments prior to their transport. The tripeptide YPI was resistant to cellular peptidases and transported through the monolayer, what suggests that the reduction in systemic blood pressure caused by this peptide may be mediated by effects at tissue level. Its pathway for transepithelial absorption was examined using inhibitors of the different mechanisms for oligopeptide transport in the intestinal tract. The main route involved in the transepithelial flux of YPI is probably the peptide H+-coupled transporter PepT1. These results highlight the
